Measuring daily activity with a wearable device in amyotrophic lateral sclerosis
Tests a wearable device that tracks daily movement in adults with ALS.
Plain-language title generated from the registry record
Registry title: Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part.
Key facts
- Where
- Liège, BelgiumSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with amyotrophic lateral sclerosis (ALS). Participants are checked every three months for a year and wear an activity sensor called Actimyo for one month after each visit.
- Age
- Over 18 years old.
- Sex
- All sexes can join.
- Disease stage
- A clinically defined or probable ALS diagnosis, by the El Escorial criteria revised with Awaji's electro-diagnostic algorithm.
- Earlier treatment
- If taking Riluzole, the dose must be stable for 1 month and continue throughout the study.
Main reasons for not taking part
- Cognitive problems that limit understanding of the tasks, or communication difficulties that hinder data collection
- Any other past or present illness that affects motor function
- Recent surgery or trauma (less than 6 months) in the arms or legs
- Neurological, endocrine, infectious, allergic, or inflammatory illness in the three weeks before joining
- Taking part in an interventional clinical trial
Read by machine on 12 November 2026.
Where in Belgium
- CHR CitadelleLiège, BelgiumContact: Laurie MEDARDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Centre Hospitalier Universitaire de Liege
- Trial code
- NCT04882904
- Record updated
- 5 December 2025
- Original description
ActiSLA is a monocentric academic study. Patients with amyotrophic lateral sclerosis may be included on a voluntary basis. The investigators plan to include a group of approximately 20 patients with ALS.Read full original descriptionShow less
Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects
ActiSLA is a monocentric academic study. Patients with amyotrophic lateral sclerosis may be included on a voluntary basis. The investigators plan to include a group of approximately 20 patients with ALS.
The investigators have planned to assess patient every three months for a year. On each visit, participants will undergo a clinical examination with MRC sum score and Ashworth scores.
They will perform few tests ( 6-minutes walk test (6MWT), dynamometric measure, electromyography, Edinburgh Cognitive and Behavioural ALS Screen ) and will answer to some questionaires (dysphagia handicap scale, ALS-SFR-r).
After each visit, participants will wear Actimyo for one month daily.
Inclusion: Clinically defined or probable diagnosis of ALS according to El Escorial criteria revised with Awaji's electro-diagnostic algorithm; Over 18 years old; Signed informed consent; If patient on Riluzole, the dosage should be stable for 1 month and continued throughout the study period.
Exclusion: Any other previous or present pathology having an impact on motor function; Recent surgery or trauma (less than 6 months) in the upper or lower limbs; Prior neurological, endocrine, infectious, allergic, or chronic or acute inflammatory pathology in the three weeks preceding inclusion; Patients with excessive cognitive disorders, limiting the understanding of task or with apparent communication difficulties hindering data collection; Patients participating in an interventional clinical trial.